Navigation Links
Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R)
Date:3/12/2010

SAN DIEGO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 12 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc. (TSX: PTI), a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products.  The financial terms of the deal were not disclosed.

"Patheon's manufacturing capabilities provide us a proven platform to help ensure successful market entry and stable commercial supply of Contrave in the event it is approved," said Mike Narachi, President and CEO of Orexigen.  "This relationship also provides the means to accelerate the development and commercialization of next generation formulations of Orexigen products."

"We have crafted a strategic, long-term partnership predicated on a shared commitment to maximizing the potential of Contrave and Empatic and to the mission of addressing the significant health issue of obesity," said Wes Wheeler, President and CEO of Patheon.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave®, has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA by the end of April.  The Company's second product, Empatic™, has completed Phase 2 clinical development.  Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches.  Further information about the Company can be found at http://www.Orexigen.com.

About Patheon

Patheon Inc. is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry.  Patheon prides itself in providing the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms.  Patheon uses many innovative technologies including single-use disposables, multi-layer tablets, pre-filled syringes and a variety of modified release technologies.  

Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization.  Patheon can take customers directly to the clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic™ programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.  

Patheon, with an integrated development and manufacturing network of 11 facilities and eight development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements.  These statements are based on the Company's current beliefs and expectations.  These forward-looking statements include statements regarding the potential for, and timing of, filing an NDA for Contrave.  The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved.  Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: risks inherent in the continued analyses of clinical trial results, including Contrave Phase 3 trials; the uncertainty of the FDA approval process and other regulatory requirements; the therapeutic and commercial value of Contrave and Empatic; reliance on third parties to assist with the development of Contrave and Empatic and the regulatory submissions related thereto; the potential for adverse safety findings relating to Contrave or Empatic; and other risks described in the Company's filings with the Securities and Exchange Commission.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.  All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

SOURCE Orexigen Therapeutics, Inc.

Back to top

RELATED LINKS
http://www.Orexigen.com

'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. ... results for the fourth quarter of 2016 on Wednesday, February 15, ... ... PM ET on Wednesday, February 15, 2017, during which management will ... other corporate activities. To participate in the conference call, please dial ...
(Date:1/19/2017)... , Jan. 19, 2017 This report on ... and future scenario of the global market. Large number ... consumption. Severe chronic constipation is a major side effect ... laxatives. Hence, novel targeted therapy has been prescribed to ... launch of targeted medicines, and growing awareness about the ...
(Date:1/19/2017)... BOSTON , Jan. 19, 2017  Stealth BioTherapeutics ... therapeutics to treat mitochondrial dysfunction, today announced new additions ... , M.D., as Chief Medical Officer, and Daniel ... Stealth announced that Jim Carr , Pharm.D. has ... "We are pleased to welcome Doug and Daniel ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a ... has set out for each of his children. “The Angel” is the creation of ... Music in New York City, and impassioned writer. , When asked of her new ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Journey to Christmas:” a beautiful and enchanting tale that teaches ... Kimberly Cordoves, a mother of three in Oklahoma City, and a devoted woman of faith. ... a book has been in the back of my mind for years, but actually doing ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Management System: an On-demand E-learning system for Clinical and Regulatory education for ... is based on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. ...
(Date:1/19/2017)... ... January 19, 2017 , ... LabRoots , ... from around the world, announces the launch of its newly redesigned website. The ... to research breakthroughs and trending news, vital information on upcoming virtual events and ...
(Date:1/19/2017)... ... January 19, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it will be co-hosting a ... innovative excipients and drug delivery solutions to health industries worldwide. The one day ...
Breaking Medicine News(10 mins):